These findings support bispecific GLP-1/GLP-2 agonism as a mechanistically distinct incretin strategy in advanced T2D
If policymakers want to expand GLP-1 coverage to include the obesity indication in Medicare, Medicaid, or the commercial insurance sector, theyll need a strategy for managing utilization and targeting populations most likely to benefit
Other autoimmune disorders: PA is frequently associated with other autoimmune conditions like Type 1 diabetes, Graves disease, Hashimotos thyroiditis and vitiligo (Vaqar S, 2023)
10.1161/CIR.0000000000000691 51 DunlayS
It never predicts dose response
A Broader Ecosystem of Care for People on GLP 1 Therapies Oura Ring and the Oura App provide continuous, biometric tracking across Sleep, Readiness, Activity, and other key physiological signals